13:30 , Dec 5, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Brain cancer Mouse studies suggest an oncolytic herpes simplex virus (HSV) expressing CDH1 could help treat glioblastoma multiforme (GBM). An oncolytic HSV was engineered to express human CDH1 to enhance cell-to-cell transmission and reduce...
05:02 , Nov 30, 2018 |  BC Innovations  |  Targets & Mechanisms

Souped-up CARs at ASH 2018

Rather than searching for new antigens, makers of the latest generation of CAR therapies are focusing on the CARs themselves by designing more sophisticated methods of targeting multiple antigens, controlling cytotoxicity and enhancing tumor-homing. BioCentury’s...
20:33 , Oct 31, 2018 |  BC Innovations  |  Distillery Techniques

Disease models

TECHNOLOGY: Animal models E-cadherin (CDH1)-deficient mice with activated PI3KCA could be used to screen therapies for invasive lobular breast carcinoma. Mice engineered to express mutant, inactive CHD1 and constitutively active PI3KCA recapitulated multiple features of...
21:28 , May 24, 2018 |  BC Extra  |  Preclinical News

miRNA-targeted circular single-stranded DNA to treat cancer

A Nankai University-based team developed a small circular single-stranded DNA molecule that inhibits cancer growth in cells and mice by sequestering microRNAs (miRNAs) that silence tumor suppressor genes. Preclinical deals in nucleic acid modalities over...
03:45 , Apr 13, 2018 |  BC Innovations  |  Targets & Mechanisms

Meeting the burden

A major theme at this year’s AACR is the abundance of preclinical discovery driven by molecular signatures in patient samples, suggesting the research community is heeding the call for studies better grounded in human data,...
00:33 , Apr 6, 2018 |  BC Innovations  |  Targets & Mechanisms

GI Band-Aid

A trio of Science papers shows a leaky gut can drive systemic inflammation and autoimmunity by allowing bacteria and their products to escape the GI lumen and enter the bloodstream. The results open a variety...
20:56 , Aug 17, 2017 |  BC Innovations  |  Finance

Built to purpose

With almost 40 start-ups engaging in build-to-buy deals since 2013 and an average 2-4 years for up or down decisions, the next year could see a spate of acquisitions -- or options declined -- that...
20:33 , Mar 30, 2017 |  BC Innovations  |  Translation in Brief

An E3 for TNBC

With the multiple myeloma drug Velcade bortezomib having put E3 ubiquitin ligases on the drug development map, scientists are now taking aim at another E3 ligase for a hard-to-treat solid tumor: triple-negative breast cancer (TNBC)....
07:00 , May 16, 2016 |  BioCentury  |  Emerging Company Profile

EMT interrupted

Oncodrone B.V. is developing a small molecule that can disrupt the epithelial-mesenchymal transition to prevent tumor cells from gaining invasive and malignant properties. The biotech plans to develop the compound for aggressive tumors such as...
07:00 , Mar 24, 2016 |  BC Innovations  |  Distillery Techniques

Techniques: E-cadherin (CDH1; CD324) mutations as diagnostic markers of plasmacytoid bladder cancer

Biomarkers TECHNOLOGY: Gene profiling Mutations in CDH1 could help diagnose the aggressive plasmacytoid subtype of bladder cancer. Genetic sequencing identified CDH1 mutations in bladder tumor samples from 20 of 25 patients with the plasmacytoid subtype...